Tenofovir IVR
Polyurethane, reservoir ring designed for up to 90 days use. First Phase I completed (CONRAD-128). Expanded Phase I trial (MTN-038) completed late 2019. The TFV IVR was also evaluated in comparison with oral Truvada for systemic and local PK and PD (CONRAD 140). A first-in-kind study to evaluate MPT IVRs in Africa (CDC Kisumu Combined Ring Study/CONRAD B17-44) was also completed late 2019.
Development Stage:
Clinical – Phase 2 Trial (C2)
Hormonal/Non-Hormonal:
Non-Contraceptive
Delivery Route & Method:
Intravaginal - Intravaginal Ring (IVR)
Mechanism of Action:
nucleoside analogue reverse transcriptase inhibitor (NRTI)
Developer:
- CONRAD
Funding:
- Centers for Disease Control and Prevention (CDC)
- National Institutes of Health (NIH)
- U.S. Agency for International Development (USAID)
Funding Mechanism:
NIH: Microbicide Trials Network (MTN)
USAID: Cooperative Agreement
Past Funding:
Bill & Melinda Gates Foundation
NIH: Interagency Agreements to USAID
Active Ingredient(s):
- Tenofovir (TFV)
Product Indication(s):
- HIV
- HSV-2